[The perioperative role of high-flow cannula oxygen (HFNO)].

Place de l’oxygénothérapie nasale à haut débit en périopératoire.
Complication respiratoire postopératoire High flow oxygen therapy Intraoperative Oxygénothérapie à haut débit Peropératoire Postoperative Postoperative respiratory complication Postopératoire

Journal

Revue des maladies respiratoires
ISSN: 1776-2588
Titre abrégé: Rev Mal Respir
Pays: France
ID NLM: 8408032

Informations de publication

Date de publication:
Jan 2023
Historique:
received: 01 02 2022
accepted: 14 11 2022
pubmed: 11 12 2022
medline: 18 1 2023
entrez: 10 12 2022
Statut: ppublish

Résumé

High-flow nasal cannula oxygen (HFNO) is commonly used during the perioperative period. Its numerous physiological benefits, satisfactory tolerance and ease of use have led to its widespread application in intensive care and post-anesthesia care units. HFNO is also used in the operating theater in multiple indications: as oxygen supplementation (associated with pressurization) prior to orotracheal intubation; in digestive and bronchial endoscopies, especially in patients at risk of hypoxemia; and in intraoperative surgery requiring spontaneous ventilation (ENT, thoracic surgery…). During the postoperative period, HFNO can be used in a curative strategy for respiratory failure or in a prophylactic strategy to prevent reintubation. In a curative approach, HFNO seems of interest following cardiac or thoracic surgery but has not been evaluated in respiratory failure subsequent to abdominal surgery, in which case noninvasive ventilation remains the gold standard. The risk of respiratory complications depends on type of surgery and on patient comorbidities. As prophylaxis, HFNO is currently preferred to conventional oxygen therapy after cardiac or thoracic surgery, especially in patients at high risk of respiratory complications. For the clinician, it is important to acknowledge the limits of HFNO and to closely monitor patients receiving HFNO, the objective being to avoid delays in intubation that could lead to increased mortality.

Identifiants

pubmed: 36496314
pii: S0761-8425(22)00375-8
doi: 10.1016/j.rmr.2022.11.004
pii:
doi:

Substances chimiques

Oxygen S88TT14065

Types de publication

English Abstract Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

61-77

Informations de copyright

Copyright © 2022 SPLF. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

T Genty (T)

Service de réanimation cardiothoracique, hôpital Marie-Lannelongue, groupe hospitalier Paris Saint-Joseph, Le Plessis-Robinson, France. Electronic address: t.genty@ghpsj.fr.

F Stéphan (F)

Service de réanimation cardiothoracique, hôpital Marie-Lannelongue, groupe hospitalier Paris Saint-Joseph, Le Plessis-Robinson, France; Université Paris-Saclay, faculté de médecine, Le Kremlin-Bicêtre, France; Inserm U999, hypertension pulmonaire : physiopathology et nouvelles thérapeutiques, hôpital Marie-Lannelongue, Le Plessis-Robinson, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH